(Total Views: 695)
Posted On: 07/05/2024 12:18:15 PM
Post# of 148870
MADRIGAL Hedging their bet with LERONLIMAB ?
Madrigal is facing a Post-Marketing study to stay on the Market. This regulatory route was created to hasten medicines to patients faster in the area of Unmet need, Butt,...THEY are still responsible for proving REZDIFFRA is Effective.
The danger in being first-to-market is a competitor in a late-stage clinical trial might kick your
@$$.
With only a single pipeline product...you become the cliched One-trick-pony.
Whereas LERONLIMAB is a platform Large Molecule.
Madrigal is targeting 315,000 patients @ $47,700.00 a year...Lots of Moolah.
Madrigal Short interest is at 4,434,720. shares..and has almost Tripled since July of 2023...at 28.36% of the existing float...with 5.6 days to cover.
DOTS anyone.?
Madrigal is facing a Post-Marketing study to stay on the Market. This regulatory route was created to hasten medicines to patients faster in the area of Unmet need, Butt,...THEY are still responsible for proving REZDIFFRA is Effective.
The danger in being first-to-market is a competitor in a late-stage clinical trial might kick your
@$$.
With only a single pipeline product...you become the cliched One-trick-pony.
Whereas LERONLIMAB is a platform Large Molecule.
Madrigal is targeting 315,000 patients @ $47,700.00 a year...Lots of Moolah.
Madrigal Short interest is at 4,434,720. shares..and has almost Tripled since July of 2023...at 28.36% of the existing float...with 5.6 days to cover.
DOTS anyone.?
(8)
(0)Scroll down for more posts ▼
